Hodgkin’s Lymphoma Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Hodgkin’s Lymphoma Information Center has current, evidence-based information for you. Get the facts about Hodgkin’s lymphoma prevention, early detection, treatment, and survivorship, and stay up to date with ongoing Hodgkin’s lymphoma research that could impact your treatment decisions through our daily cancer news.
You are not alone—The CancerConnect Hodgkin’s Lymphoma Community is the leading Social Media Application for Hodgkin’s Lymphoma patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
Improved progression-free survival Keytruda PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma
Overall 66% of HL patients refractory to treatment responded. PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma
On the basis of these results, the US Food and Drug Administration has granted nivolumab a breakthrough therapy designation in relapsed HL, and a phase 2 study is under way.
Cancer and its treatment can come with a variety of complications, some more serious... Advanced Directives
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse... Caregivers
What is Caregiving and Who are Caregivers? Caregivers are individuals who provide...
Hodgkin’s Lymphoma Management
Sean Swarner is a master of setting a goal and achieving it. So when he... Moving Bodies, Changing Lives
Moving On Aerobics helps women regain joy of movement and physical fitness after... Where Kids Can Be Kids… And Cancer Takes a Back Seat
Cancer camps for kids provide fun and camaraderie for children facing down a cancer...
Hodgkin’s Lymphoma Clinical Trials
COGAHOD0431 – Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low-Risk Hodgkin Disease
COGAHOD03P1 – Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease
COGAHOD04B1 – Hodgkin Disease (HD) Banking Study.